Date of Award
5-2019
Document Type
Honors Thesis
Department/Major
Basic Biomedical Science
First Advisor
Dr. Victor Huber
Second Advisor
Dr. Daniel Bird
Third Advisor
Professor Beate Wone
Keywords
systemic sclerosis, CD19, MEDI-551
Subject Categories
Medical Cell Biology | Medical Immunology | Medical Microbiology
Abstract
Systemic sclerosis, a subcategory of scleroderma, is a rare autoimmune disease that affects the skin and, in some cases, the internal organs of those diagnosed with the disease. There is currently no cure for this disease, only treatments to slow its progression. It is important to note that each individual diagnosed with scleroderma experience differences in severity and symptoms of the disease and are treated based on their symptoms, not as a whole. Many factors of this disease still remain unknown, such as what causes the disease or stimulates the onset of it. Recent studies have helped determine different treatment options for those diagnosed with the disease. For example, studies have been conducted using MEDI-551 , a monoclonal antibody that targets CD19 transmembrane proteins, as form of treatment that could further improve systemic sclerosis. Here we present an initial evaluation of antibody therapies on whole cells as a way to start testing a therapeutic like MEDI-551 for its efficacy in kilting B cells through either direct or indirect interactions with the immune system. Our findings discussed in the context of the disease state and the future of treatment using monoclonal antibody therapies.
Recommended Citation
Dohman, Natalia, "DEVELOPMENT OF METHODS TO EVALUATE THE USE OF MEDI-551 TO TARGET CD19 TRANSMEMBRANE PROTEINS ON B-CELLS TO IMPROVE SYSTEMIC SCLEROSIS" (2019). Honors Thesis. 222.
https://red.library.usd.edu/honors-thesis/222